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Montserrat Dı́az10, Nàdia Martı́n11, Xoana Barros11, Helena Marco12,
Maruja Isabel Navarro12, Noemı́ Esparza13, Sandra Elias14, Ana Coloma15,
Nicolás Roberto Robles16, Irene Agraz17, Esteban Poch18,19, Lida Rodas18,19,
Vı́ctor Lozano18,19, Beatriz Fernández20, Eduardo Hernández3,
Maria Isabel Martı́nez4, Ramona Ionela Stanescu4, José Pelayo Moirón6,
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Background. Diabetic patients with kidney disease have a high prevalence of non-diabetic renal disease (NDRD). Renal and
patient survival regarding the diagnosis of diabetic nephropathy (DN) or NDRD have not been widely studied. The aim of
our study is to evaluate the prevalence of NDRD in patients with diabetes and to determine the capacity of clinical and
analytical data in the prediction of NDRD. In addition, we will study renal and patient prognosis according to the renal
biopsy findings in patients with diabetes.
Methods. Retrospective multicentre observational study of renal biopsies performed in patients with diabetes from 2002 to
2014.
Results. In total, 832 patients were included: 621 men (74.6%), mean age of 61.7 6 12.8 years, creatinine was 2.8 6 2.2 mg/dL
and proteinuria 2.7 (interquartile range: 1.2–5.4) g/24 h. About 39.5% (n¼329) of patients had DN, 49.6% (n¼413) NDRD and
10.8% (n¼90) mixed forms. The most frequent NDRD was nephroangiosclerosis (NAS) (n¼87, 9.3%). In the multivariate
logistic regression analysis, older age [odds ratio (OR) ¼ 1.03, 95% CI: 1.02–1.05, P<0.001], microhaematuria (OR ¼ 1.51, 95%
CI: 1.03–2.21, P¼0.033) and absence of diabetic retinopathy (DR) (OR ¼ 0.28, 95% CI: 0.19–0.42, P<0.001) were independently
associated with NDRD. Kaplan–Meier analysis showed that patients with DN or mixed forms presented worse renal
prognosis than NDRD (P<0.001) and higher mortality (P¼0.029). In multivariate Cox analyses, older age (P<0.001), higher
serum creatinine (P<0.001), higher proteinuria (P<0.001), DR (P¼0.007) and DN (P<0.001) were independent risk factors for
renal replacement therapy. In addition, older age (P<0.001), peripheral vascular disease (P¼0.002), higher creatinine
(P¼0.01) and DN (P¼0.015) were independent risk factors for mortality.
Conclusions. The most frequent cause of NDRD is NAS. Elderly patients with microhaematuria and the absence of DR are
the ones at risk for NDRD. Patients with DN presented worse renal prognosis and higher mortality than those with NDRD.
These results suggest that in some patients with diabetes, kidney biopsy may be useful for an accurate renal diagnosis and
subsequently treatment and prognosis.
Keywords: chronic kidney disease, diabetes mellitus, diabetic nephropathy, non-diabetic renal disease, renal biopsy
INTRODUCTION
Diabetes mellitus (DM) is one of the most important health
problems in the world and it is dramatically increasing in fre-
quency [1]. One of the reasons is the progressive ageing of the
population, along with the increase in overweight, obesity, un-
healthy diets and physical inactivity, factors that increase the
prevalence of this type of chronic disease. Currently, there are
about 500 million people affected by DM worldwide. It is
expected that by the year 2045, this number will have increased
to about 693 million [2]. This increase will be more relevant in
underdeveloped countries, such as Southeast Asia, South and
Central America or Africa, where it is expected to increase by up
to 150% [2]. Furthermore, DM is an important cause of chronic
disease. In fact, in the last two decades, DM proportion has es-
calated up to 79% as a cause of years lived with disability (YLD).
In men, it is the second cause of YLD and in women, the third,
surpassed by chronic lumbar pain in both sexes and headaches
in the case of women [3].
Chronic kidney disease will develop in between 30% and 40%
of patients with Type 1 or Type 2 diabetes [4, 5]. DM is now the
first cause of progressive renal disease that leads to end-stage
renal disease (ESRD) and subsequently the need of renal re-
placement therapy (RRT) [6–8]. In diabetic patients, the presence
of albuminuria is an independent risk factor for mortality. This
mortality increases exponentially when albuminuria and a de-
crease in glomerular filtration rate (GFR) are associated [9]. The
coexistence of DM and other cardiovascular risk factors such as
smoking, hypertension (HTA) and dyslipidaemia exponentially
raises the cardiovascular mortality rate of these patients [7].
The renal involvement of patients with diabetes is very het-
erogeneous, and when biopsied almost two-thirds of them are
diagnosed with non-diabetic renal disease (NDRD) [10–12]. This
high prevalence of NDRD among biopsied patients with diabetes
may be related to the fact that the renal biopsy in diabetic
patients is usually performed to rule out other causes of renal
disease [13, 14]. The role of renal biopsy in patients with diabe-
tes has been under discussion for years [15]. In this context, co-
hort studies have been carried out with biopsied diabetic
patients. Most studies are retrospective and unicentric with a
variable cohort size [16, 17]. In these populations, the preva-
lence and risk factors of NDRD versus diabetic nephropathy
(DN) have been studied [11, 12, 18–25]. As the renal prognosis is
worse in DN than in NDRD patients, the diagnosis of renal inju-
ries may be helpful to stratify our diabetic patients [19, 25–27].
However, until now, no differences have been found in survival
between DN and NDRD patients [12].
The aim of our study is to analyse, with a multicentric study,
the prevalence of NDRD in a cohort of biopsied patients with di-
abetes. In addition, we also plan to study whether clinical and
analytical data may be useful to predict NDRD in patients with
diabetes and renal involvement. Finally, we plan to find differ-
ences in renal and patient prognosis according to the diagnosis
in the renal biopsy (DN versus NDRD).
MATERIALS AND METHODS
Patients
This retrospective cohort study was performed in 18 nephrology
departments from the Spanish Group for the Study of
Glomerular diseases (GLOSEN), the Catalonian Group for the
Study of Glomerular diseases (GLOMCAT) and the Spanish
Group of Diabetic Nephropathy (GEENDIAB). Data from renal bi-
opsies performed in patients with diabetes from 2002 to 2014
were collected. Patient identification was performed by reviewing
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histopathological charts and clinical histories. The Medical Ethics
Committee of Parc de Salut Mar, Barcelona, Spain approved the
study protocol; the approval number is CEIC2013/5468/I.
Variables studied
A total of 112 variables were studied: 58 (51.8%) were clinical
and 54 (48.2%) were laboratory data. Patient demographic char-
acteristics were recorded (age, gender and race), along with
history of HTA, dyslipidaemia, duration of DM, presence or ab-
sence of diabetic retinopathy (DR), diabetic neuropathy, ischae-
mic heart disease, previous stroke, peripheral vascular disease,
malignancy, systemic disease, and treatment with renin–angio-
tensin–aldosterone system blockers (RAASB), oral antidiabetics,
insulin, statin and aldosterone antagonists.
At the time of renal biopsy, weight, height, systolic blood
pressure (BP) and diastolic BP were recorded. In terms of labora-
tory data, renal function [serum creatinine in milligram per
deciliter and estimated glomerular filtration rate (eGFR) accord-
ing to Modification of Diet in Renal Disease-4 in mL/min/
1.73 m2], urea in milligram per decilitre, fasting blood glucose
levels in milligram per deciliter, proteinuria (g/24 h), microhae-
maturia, autoimmune markers [antinuclear antibodies (ANAs),
Anti-double stranded DNA (Anti-DsDNA), Anti-neutrophil cyto-
plasmic antibodies (ANCAs), Anti-Glomerular Basement
Membrane (anti-GBM) and cryoglobulins] and viral serology
(anti-Hepatitis C Virus (HCV), surface antigen of the hepatitis B
virus (HBsAg) and anti-Human Immunodeficency Virus (anti-
HIV)) were all examined.
The indications of renal biopsy such as nephrotic syndrome,
acute kidney injury (AKI), nephrotic proteinuria in patients with
diabetes and <5 years of evolution, nephrotic proteinuria with-
out DR, abrupt decrease in eGFR, micro/macrohaematuria, signs
or symptoms of systemic disease and proteinuria >1 g (excluded
nephrotic) in patients with diabetes and <5 years of evolution
were also recorded.
Renal biopsies were reviewed for this study at every partic-
ipating centre. The morphological characteristics found in the
biopsy (number of glomeruli, diffuse or nodular mesangial ex-
pansion, global or segmental sclerosis, percentage of glomeru-
losclerosis and increase of basement glomerular membrane)
and the final diagnoses were collected. Based on the diagno-
ses, the renal biopsies were classified into three categories:
isolated DN, NDRD or DN-superimposed NDRD (DN plus
NDRD) [11].
Finally, the follow-up was assessed at 1, 3, 5 and 10 years
post-renal biopsy. The variables evaluated were renal function
(creatinine level and GFR), urea concentration, fasting blood glu-
cose, 24-h proteinuria, microalbuminuria, urine protein/creati-
nine ratio, need for RRT and death.
Statistical analysis
Statistical analysis was performed using IBM’s SPSS Statistics
version 20.0. The variables are expressed in mean and standard
deviation and the qualitative variables in percentages. The dis-
tribution of variables was assessed using the Kolmogorov–
Smirnov test. Univariate comparisons between groups were
performed using a Chi-squared test for categorical variables
and one-way analysis of variance test for comparing means. A
multivariate analysis of variables considered as potential pre-
dictors of DN versus NDRD (dependent variable) was performed
using binary logistic regression. Regarding the study of survival
and the need for RRT, Kaplan–Meier curves and log-rank tests
were performed. For the multivariate analysis, the Cox regres-
sion was performed to find the risk factors for mortality and
for the start of RRT. A P < 0.05 was considered a statistically
significant difference.
RESULTS
Baseline characteristics of the population
A total of 832 patients with diabetes and kidney biopsy were in-
cluded in the study. The most relevant clinical and analytical
data at the time of renal biopsy are summarized in Table 1.
Patients were classified according to the pathological diagnosis:
DN, NDRD or DN plus NDRD (mixed forms). The average age of
the population was 61.7 6 12.8 years old; however, the patients
with NDRD were older (P< 0.05). About 74.6% (n¼ 621) of the
patients were men. Some 7.1% of the total patients (n¼ 59) had
Type 1 DM, and a significantly greater proportion was observed
in the isolated DN group. In total, 722 patients (87%) had HTA.
The predominant race was Caucasian (n¼ 646, 77.6%) in all
groups. The average duration of DM was 10.8 6 8.6 years, and
patients with NDRD had a significantly shorter time of evolution
of DM. About 26.6% of patients (n¼ 221) had DR, with a higher
proportion in cases with DN (P< 0.05). The mean creatinine level
was 2.8 6 2.2 mg/dL and patients with NDRD had a significantly
worse renal function (P< 0.05). The median (interquartile range
25–75) proteinuria was 2.7 (1.2–5.4) g/24 h and there were no dif-
ferences between the three groups. Microhaematuria was ob-
served in 34.6% (n¼ 288) of the cases, most frequently in the
NDRD group. It is relevant to highlight that one-third of patients
with isolated DN have microhaematuria.
The markers of systemic disease are summarized in the
Supplementary data, Table S1. Serologic testing positive for
ANA and ANCA was found more commonly in patients with di-
abetes and NDRD at kidney biopsy (P< 0.05).
Indications for renal biopsy
The indications for renal biopsy are summarized in Table 2. The
most frequent indication for renal biopsy in all studied patients
was nephrotic syndrome (n¼ 261, 31.4%), followed by abrupt re-
duction of eGFR in patient with previous stable renal function
(n¼ 173, 20.8%), AKI (n¼ 118, 14.2%), nephrotic proteinuria with-
out DR (n¼ 89, 10.7%), signs or symptoms of systemic disease
(n¼ 53, 6.4%), proteinuria >1 g with DM <5 years of evolution
(n¼ 46, 5.5%), micro/macrohaematuria (n¼ 42, 5%) and ne-
phrotic proteinuria with DM <5 years of evolution (n¼ 18, 2.2%).
Interestingly in NDRD patients, haematuria, AKI and the suspi-
cion of systemic disease were more frequent as a reason for re-
nal biopsy (P< 0.001). Among the patients with haematuria,
69.1% were diagnosed with NDRD. AKI was both the indication
for renal biopsy in 66.1% of the cases and the suspicion of sys-
temic disease in 67.9% of NDRD as compared with DN patients
(Table 2).
Results of renal biopsy
DN was diagnosed in 39.5% (n¼ 329) of patients, NDRD in 49.6%
(n¼ 413) and DN-superimposed NDRD in 10.8% (n¼ 90). The
most frequent NDRD was benign nephroangiosclerosis (NAS)
(n¼ 87, 9.3%), followed by immunoglobulin A (IgA) nephropathy
(IgAN) (n¼ 44, 4.7%), membranous nephropathy (MN) (n¼ 43,
4.6%), acute interstitial nephritis (AIN) (n¼ 40, 4.3%), acute tubu-
lar necrosis (n¼ 26, 2.8%), focal segmental glomerulosclerosis
(n¼ 25, 2.7%) and extracapillary glomerulonephritis (n¼ 20,
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2.1%). The other NDRD diagnoses were less represented in the
cohort (Figure 1). About 3.7% (n¼ 34) of patients did not have a
diagnosis because the glomeruli were sclerotic, and 2.8% (n¼ 26)
were unclassifiable because they did not have enough material.
Predictive factors for non-diabetic nephropathy
To identify the predictors of NDRD, a multivariate binary logistic
regression analysis was performed including the variables with
statistical significance in the bivaritate analyses: age, creati-
nine, the presence of microhaematuria, time duration of DM
and the presence of DR (Table 3). The independent risk factors
for NDRD were the presence of microhaematuria, older age and
the absence of DR. The model’s discriminatory capacity
obtained a receiver operating characteristic curve with an area
under the curve of 0.721 (95% confidence interval 0.677–0.765)
(Supplementary data, Figure S2).
Renal prognosis and survival
Actuarial survival analyses of the study cohort and renal prog-
nosis (need for RRT) were performed. About 38.6% (n¼ 321) of
the patients needed RRT during the follow-up period. Of these
patients, 50.2% were affected by DN (n¼ 165), 27.8% (n¼ 115) of
patients with NDRD and 45.6% (n¼ 41) with mixed forms. The
overall mortality of the patients at 10-year post-renal biopsy
was 21.6% (n¼ 180), of which 46.1% (n¼ 83) were diagnosed with
DN, 40.6% (n¼ 73) with NDRD and 13.3% (n¼ 24) with mixed
forms. Survival analysis using Kaplan–Meier curves showed
that patients with DN or NDRD plus DN presented worse renal
prognosis than NDRD (log-rank test P< 0.001) and higher mor-
tality (log-rank test, P¼ 0.029; see Figure 2). It is important to
mention that differences in renal prognosis are evident very
early after renal biopsy. In the multivariate Cox analysis ad-
justed by sex, age, creatinine, proteinuria, treatment with
RAASB, ischaemic heart disease, peripheral vascular disease,
DR and diagnosis in renal biopsy of DN, older patients
(P< 0.001), higher creatinine level (P< 0.001), higher proteinuria
(P< 0.001), the presence of DR (P¼ 0.007) and the diagnostic of
DN (P< 0.001) were identified as risk factors for RRT. In addition,
older patients (P< 0.001), peripheral vascular disease (P¼ 0.002),
higher creatinine level (P¼ 0.01) and the diagnostic of DN in re-
nal biopsy (P¼ 0.015) were identified as independent risk factors
for mortality (Table 4).
Table 1. Baseline characteristics of the population
Characteristics All patients DN NDRD plus DN NDRD P-value
Patients, n (%) 832 (100) 329 (39.5) 90 (10.8) 413 (49.6) –
Age, years 61.7 6 12.8 59 6 12.8 62.3 6 12.1 63.7 6 12.6 <0.001
Male sex, n (%) 621 (74.6) 245 (74.5) 72 (80) 304 (73.6) 0.449
Type 1 DM, n (%) 59 (7.1) 37 (11.2) 8 (8.9) 14 (3.4) <0.001
HTA, n (%) 722 (87) 293 (89.6) 77 (85.6) 352 (86) 0.275
Systolic BP, mmHg 144 6 25 150 6 26 150 6 25 138 6 23 <0.001
Diastolic BP, mmHg 77 6 12 79 6 13 77 6 12 75 6 12 0.015
Race, n (%)
Caucasian 646 (77.6) 234 (94) 71 (94.7) 341 (94.2)
Black 4 (0.5) 2 (0.8) 0 2 (2.7) 0.069
Asiatic 7 (0.8) 1 (0.4) 0 6 (1.7)
Unknown 29 (3.5) 12 (4.8) 2 (2.7) 15 (4.1)
Duration of DM, years 10.8 6 8.6 12.2 6 8.4 12.1 6 9.3 9.4 6 8.5 <0.001
DR, n (%) 221 (26.6) 145 (44.1) 30 (33.3) 46 (11.1) <0.001
Creatinine, mg/dL 2.8 6 2.2 2.6 6 1.7 3.5 6 3.1 2.9 6 2.3 0.003
eGFR (MDRD-4) 38.2 6 27.5 40.2 6 26 32.7 6 27.7 37.9 6 28.3 0.133
Proteinuria, g/24 h 2.7 (1.2–5.4) 3.2 (3.9–4.9) 2.5 (2.8–4.7) 2.4 (3.4–4.3) 0.254
Microhaematuria, n (%) 288 (34.6) 93 (33.7) 38 (45.2) 157 (47.9) 0.001
Fasting plasma glucose, mg/dL 138.5 6 64 143.2 6 66.8 140.4 6 65.3 134.3 6 60.5 0.179
Statistical analysis: analysis of variance. MDRD, Modification of Diet in Renal Disease. Data are presented as mean 6 SD or median (interquartile range, 25–75) unless
otherwise indicated. Bold values: P <0.05. DM, diabetes mellitus; HTA, hypertension; BP, blood pressure; DR, diabetic retinopathy, eGFR, estimated glomerular filtration rate.
Note: Bold values are with statistical significance.
Table 2. Indications of renal biopsy
Indications DN NDRD plus DN NDRD
Patients, n (%) 329 (39.5) 90 (10.8) 413 (49.6)
Nephrotic syndrome or fast increase of proteinuria, n (%) 138 (52.9) 28 (10.7) 95 (36.4)
Abrupt decrease in eGFR in patient with stable renal function, n (%) 76 (43.9) 21 (12.1) 76 (43.9)
AKI, n (%) 23 (19.5) 17 (14.4) 78 (66.1)
Nephrotic proteinuria without DR, n (%) 36 (40.4) 7 (7.0) 46 (51.7)
Signs of symptoms of systemic disease, n (%) 13 (24.5) 4 (7.5) 36 (67.9)
Proteinuria >1 g in DM with <5 years of evolution, n (%) 16 (34.8) 5 (10.9) 25 (54.3)
Micro/macrohaematuria, n (%) 11 (26.2) 5 (11.9) 26 (61.9)
Nephrotic proteinuria with DM <5 years of evolution, n (%) 6 (33.3) 1 (5.6) 11 (61.1)
Others, n (%) 10 (31.3) 2 (6.3) 20 (62.5)
AKI, acute kidney injury.










In our studied cohort of 832 patients with DM, the largest
European study to date of renal biopsy findings in patients with
diabetes, approximately two-thirds of the patients had NDRD as
a unique or contributing cause of renal disease. The most fre-
quent indication of renal biopsy was nephrotic syndrome. In
our study, the first cause of NDRD was benign NAS. We found
that microhaematuria, older age and absence of DR were inde-
pendent predictors of NDRD in renal biopsy in diabetic patients.
Our results reinforce the clinical belief that diabetic patients
with microhaematuria, older age and without DR are more
prone to develop NDRD. Regarding the renal prognosis, we
found that patients with DN or DN plus NDRD presented a
higher risk of needing RRT than patients with NDRD. In addi-
tion, older age, higher creatinine level, higher proteinuria, DR
and DN involvement were identified as independent risk factors
for the need of RRT. Patients with biopsy-proven DN or mixed
forms also had a higher mortality rate when compared with
those with NDRD. In addition, older age, higher creatinine level,
the presence of peripheral vascular disease and the diagnostic
of DN in renal biopsy were identified as risk factors for
mortality.
Previous studies focused on renal biopsies of diabetic
patients with >100 patients are summarized in Table 5 [11, 18,
19, 22, 26, 28–40]. We must take into consideration that most of
these studies are retrospective and include <250 patients [12,
18, 19, 22–24, 26, 29, 32, 35, 40–43]. In our study, we strived to col-
lect data of 832 kidney biopsies performed in 18 Spanish
centres. For this purpose, three working groups participated in
this study: GLOSEN, GLOMCAT and GEENDIAB. To our knowl-
edge, this is the largest study performed in Europe.
The indication of renal biopsy in general clinical practice in
patients with diabetes is usually prompted by the clinical suspi-
cion of NDRD [6, 10, 13, 14]. Thus, the indications for renal bi-
opsy in our study correspond to those described in the
literature: nephrotic syndrome, abrupt reduction of eGFR in a
patient with previous stable renal function, renal failure, ne-
phrotic proteinuria without DR, signs or symptoms of systemic
disease, proteinuria >1 g with DM <5 years of evolution, micro/
macrohaematuria and nephrotic proteinuria with DM <5 years
of evolution. In concordance with our study, Liu et al. [28], in a
Chinese cohort of biopsied diabetic patients, showed that the
most frequent indication for kidney biopsy in patients with dia-
betes was nephrotic syndrome. In our study, we observed that
nephrotic syndrome was more frequent in patients with iso-
lated DN [12]. As expected, it is worthy of mention that haema-
turia, AKI and suspicion of systemic disease were mainly
observed in NDRD patients. As in our study, according to Liu
et al. [28], AKI and microhaematuria as indications of renal bi-
opsy are associated with NDRD in diabetic patients.
The results of the renal biopsy diagnoses, namely DN, NDRD
or mixed forms, in diabetic patients are variable: biopsy-proven
DN is diagnosed in from 6.5% to 73.9%, NDRD from 18.2% to
82.9% and mixed forms from 4% to 45.5% [11, 18–20, 22, 26, 28–
39]. In our study, the percentage of DN was 39.5%, NDRD 49.6%
and mixed forms 10.8%. In concordance, Sharma et al. [11] and
Liu et al. [28] found 44.7% and 37% of biopsy-proven DN, respec-
tively. The most frequent NDRD in the previously published
studies was IgAN [12, 21, 27, 33, 39, 40, 43, 44], followed by focal
segmental glomerulosclerosis [18, 23, 32, 45], MN [19, 28, 38] and
AIN [36, 41, 42]. Surprisingly, in our Spanish cohort, the most
frequent cause of NDRD was benign NAS. Whether this differ-
ence may be related to a higher prevalence of HTA in our cohort
of biopsied diabetic patients (87%) as compared with the other
cohorts is unknown. As compared with our cohort, the percent-
age of HTA in the Chinese study was 50.8% [28]; however, in the
rest of the studies, the prevalence of HTA was similar to our
population [21, 22, 26–29, 33, 40, 41, 46].
In the present study, older age, presence of microhaematuria
and absence of DR were identified as independent risk factors
for NDRD. Previous studies also identified older age [12], pres-
ence of microhaematuria [21, 26, 29, 33, 46] and absence of DR
[12, 19, 25, 26, 29, 33, 42] as risk factors for NDRD. The fact that
microhaematuria and DR were associated with NDRD was
expected; however, it is interesting to note that our study con-
firms that older age in patients with diabetes is a risk factor for
NDRD. These results suggest that in older patients with diabe-
tes, renal biopsy should be indicated under the minimal suspi-
cion of non-diabetic kidney disease. In addition, some studies
identified lower BP [46], elevated haemoglobin [19, 29], lower
glycosylated haemoglobin (HbA1c) [29], elevated proteinuria [33]
and decreased creatinine level [26] as risk factors for NDRD. In
other studies, increased creatinine level [12, 42] and lower pro-
teinuria [12, 21, 26] were also identified as independent risk fac-
tors for NDRD. Even though a shorter duration of DM has been
identified as an independent risk factor for NDRD [11, 12, 19, 22,
24, 26, 27, 29, 43, 46], our study was not able to confirm it in the
multivariate analysis. The discordance of these results regard-
ing the DM duration may be in part related to the unreliability
of this data, as patients frequently do not know when Type 2 di-
abetes started and their diagnosis may have been delayed.
Fiorentino et al. [16] concluded, in a recent meta-analysis with a
FIGURE 1: Diagnosis from renal biopsy: distribution of the number of patients
according to their diagnosis in renal biopsy. GN, glomerulonephritis; FSGS, focal
segmental glomerulosclerosis.
Table 3. Predictive factors for NDRD in diabetic patients
Parameter OR (95% CI) P-value
Microhaematuria (yes/no) 1.51 (1.03–2.21) 0.033
Age, years 1.03 (1.02–1.05) <0.001
DR (yes/no) 0.28 (0.19–0.42) <0.001
Time of duration of DM, years 0.98 (0.96–1) 0.086
Multivariate binary logistic regression analysis. Dependent variable: NDRD. OR:
odds ratio; 95% CI: confidence interval of 95%.
Note: Bold values are with statistical significance.
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total of 48 studies (n¼ 4876) of biopsies performed in patients
with diabetes, that a lower systolic BP, lower level of HbA1c,
shorter duration of DM and absence of DR were predictors of
NDRD. Higher creatinine level was a predictor of DN, and the
higher level of creatinine and lower GFR were an indicator for
the superimposed DN plus NDRD.
Table 4. Multivariate Cox regression analysis for need of RRT and mortality
Variables HR (95% CI) P-value
Need of renal replacement therapy
Model 1: Age, sex, ischaemic heart disease, peripheral vascular disease, DR, creatinine, proteinuria, treatment with RAASB and DN
Age, years 1.017 (1.006–1.028) <0.001
Sex (men versus women) 1.251 (0.918–1.706) 0.155
Ischaemic heart disease (yes versus no) 1.270 (0.907–1.777) 0.164
Peripheral vascular disease (yes versus no) 1.209 (0.873–1.673) 0.253
DR (yes versus no) 1.506 (1.121–2.024) 0.007
Creatinine, mg/dL 1.276 (1.224–1.330) <0.001
Proteinuria, g/24 h 1.060 (1.032–1.088) <0.001
Treatment with RAASB (yes versus no) 1.076 (0.791–1.466) 0.641
DN (DN versus NDRD/NDRD plus DN) 1.900 (1.425–2.533) <0.001
Mortality
Model 2: Age, sex, ischaemic heart disease, peripheral vascular disease, DR, creatinine, proteinuria, treatment with RAASB and DN
Age, years 1.039 (1.022–1.057) <0.001
Sex (men versus women) 1.305 (0.870–1.957) 0.198
Ischaemic heart disease (yes versus no) 1.003 (0.643–1.563) 0.99
Peripheral vascular disease (yes versus no) 1.878 (1.252–2.818) 0.002
DR (yes versus no) 1.191 (0.787–1.802) 0.409
Creatinine, mg/dL 1.100 (1.023–1.182) 0.01
Proteinuria (g/24 h) 1.019 (0.981–1.059) 0.322
Treatment with RAASB (yes versus no) 1.165 (0.773–1.755) 0.466
DN (DN versus NDRD/NDRD plus DN) 1.591 (1.096–2.308) 0.015
HR, hazard ratio; CI, confidence interval. DR, diabetic retinopathy; RAASB, renin angiotensin system blockade; DN, diabetic nephropathy. Bold values: P<0.05.
Note: Bold values are with statistical significance.
FIGURE 2: Renal and patient survival curves in all groups studied. Analysis using Kaplan–Meier of the different groups divided according to renal diagnoses: NDRD, DN
and mixed forms (DN plus NDRD). (A) Renal replacement therapy (RRT). (B) Mortality. The need of RRT (log-rank test P< 0.001) and mortality (log-rank test P¼0.029)
were significantly increased in biopsy-proven DN patients.
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When we analysed the renal prognosis, we confirmed that
biopsy-proven DN is a risk factor for ESRD. Previous studies had
shown that patients with DN had worse renal prognosis [12, 19,
25–27]. Age, DR, serum creatinine, proteinuria and DN were
identified as risk factors for ESRD. Wong et al. also identified a
higher level of serum creatinine and proteinuria as risk factors
for renal disease progression [27]. Proteinuria is a classic risk
factor for ESRD in diabetic patients [1, 12]. Some studies with
lower numbers of patients also found the presence of DR as an
independent risk factor for ESRD [19]. Chang et al. performed
two Cox regression models to identify the independent risk
factors for ESRD. In the first model, higher creatinine level,
higher systolic BP, longer duration of DM and the presence of
DN in the renal biopsy were the identified risk factors.
Surprisingly, in the second model, when the presence of DR was
added, the duration of DM and the presence of DN were no lon-
ger considered risk factors for ESRD [19]. In our study, which in-
cluded DR in the analysis, the presence of DN in the renal
biopsy persists as an independent risk factor for ESRD. These
results reinforce the knowledge that the diagnosis of NDRD in
diabetic patients should be performed, proving that it is crucial,
because these patients may benefit from specific treatments
Table 5. Main characteristics, histological findings and predictive factors for NDRD in biopsied diabetic patients (with n >100 patients)
Study (year)
Patients




n (%) Most common NDRD, n (%) Risk factors for NDRD
Current study 832 329 (39.5) 413 (49.6) 90 (10.8) Hypertensive nephrosclerosis (87,
9.7%), IgAN (44, 4.7%), MN (43, 4.6%)
Older age, microhaematu-
ria, absence of DR
Liu et al. [28] 1604 717 (44.7) 787 (49.1) 100 (6.2) MN (630, 39.3%), IgAN (287, 17.9%),
MCD (215, 13.4%)
–
Imtiaz et al. [22] 206 74 (35.9) 87 (42.2) 45 (21.8) – Shorter duration of DM
Liu et al. [29] 200 93 (46.5) 107 (53.5) – IgAN (65, 32.7%), MN (37, 18.7%), FSGS
(11, 5.6%)
Higher level of Hb, micro-
haematuria, shorter du-
ration DM, lower BP,
lower level of HbA1c
Zhuo et al. [40] 210 14 (6.5) 174 (82.9) 22 (10.7) IgAN (62, 28.7%), MN (35, 16.2%), FSGS
(6, 2.8%)
–
Sharma et al. [11] 620 227 (37) 220 (36) 164 (27) ATN (109, 17.8), FSGS (69, 11.3%), hy-
pertensive neprhosclerosis (70,
11.5%), IgAN (35, 5, 7%)
Shorter duration of DM
Byun et al. [26] 110 41 (37.3) 59 (53.6) 10 (9.1) IgAN (48, 43.5%), MN (16, 14.5%), cres-
centic GN (8, 7.2%)
Absence of DR, shorter du-
ration of DM, lower level
of proteinuria, lower level
of creatinine
Oh et al. [30] 126 50 (39.7) 65 (51.6) 11 (8.7) IgAN (20, 16%), MN (15, 11.9%), FSGS
(10, 7.6%), MPGN (6, 4.7%)
–
Chong et al. [31] 110 69 (62.7) 20 (18.2) 21 (19.1) AIN (54, 48.8%), hypertensive nephro-
sclerosis (27, 24.4%), MCD (8, 7.3%)
AKI, absence of DR
Haider et al. [32] 567 207 (38.1) 174 (32) 162 (29.8) FSGS (92, 17%), AIN (71, 13%), IgAN (49,
9%), MN (16, 3%)
–
Chang et al. [19] 119 43 (36.2) 64 (53.8) 12 (10) MN (39, 32.9%), MCD (19, 15.8%), FSGS
(14, 11.8%), IgAN (14, 11.8%)
Higher level of Hb, absence
of DR, shorter duration of
DM
Bi et al. [33] 220 120 (54.5) – 100 (45.5) IgAN (75, 34%), MN (48, 22%), mesan-
gial-proliferative GN (31, 14%)
Microhaematuria, higher
level of proteinuria, ab-
sence of DR
Zhang et al. [34] 130 96 (73.9) 34 (26.1) – IgAN (22, 16.9%), MN (8, 6.15%) –
Zhou et al. [35] 110 60 (54.5) 50 (45.5) – IgAN (37, 34%), MN (24, 22%), MPGN
(15, 14%)
–
Pham et al. [18] 232 64 (27.5) 123 (53.2) 45 (19.3) FSGS (49, 21%), MCD (35, 15.3%), IgAN
(35, 15.3%), MN (31, 13.3%)
–
Soni et al. [36] 160 44 (27.5) 68 (42.5) 48 (30) AIN (29, 18.1%), post-infectious GN (28,
17.2%), MN (18, 11.2%), FSGS (12,
7.7%)
–
Rychlı́k et al. [37] 163 69 (42.4) 77 (47.5) 17 (10.1) IgAN (25, 15%), MN (20, 12%), PICGN
(19, 11.5%)
–
Mazzucco et al. [38] 393 156 (39.7) 169 (43) 68 (17.3) MN (91, 23.1%), IgAN (80, 20.3%), post-
infectious GN (82, 20.9%), MCD (49,
12.4%)
–
Suzuki et al. [39] 109 80 (73.3) – 29 (26.7) IgAN (49, 44.8%), proliferative GN (41,
37.9%), MN (8, 6.9%), AIN (8, 6.9%),
FSGS (4, 3.4%)
–
FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; ATN, acute tubular necrosis; GN, glomerulonephritis; PICGN, pauci-inmune crescentic glo-
merulonephritis; MPGN, membrano-proliferative glomerulonephritis; Hb, haemoglobin. Note: Bold values are with statistical significance.
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and thus achieve a better renal prognosis than patients with di-
abetes and biopsy-proven DN. As shown in our previous study,
treatment with RAASB did not modify the renal prognosis
in biopsied diabetic patients [27]. Probably, the RAASB confers
a better renal protection in early stages of DM. The mean dura-
tion of DM in this cohort is 11 years, so the renal histological
changes might be too advanced. Another reason for this may
be possibly explained by a bias in patient selection, as renal
biopsy in diabetic patients is currently performed under the
suspicion of another NDRD, AKI or heavy proteinuria, among
others.
Regarding patient survival, we found that biopsy-proven DN
was a risk factor for mortality. There is only one study with dia-
betic patients in which patient survival was compared between
DN and NDRD, and no differences were found between the two
groups [12]. To our knowledge, our study is the first that identi-
fied older age, peripheral vascular disease, increased creatinine
level and DN as risk factors for mortality in a biopsied cohort of
patients diagnosed with diabetes. Older age, peripheral vascular
disease and increased serum creatinine level are risk factors
clearly related to the DM complications previously described for
mortality in diabetic patients, indicating that these risk factors
are maintained when kidney biopsy was performed [9]. More in-
terestingly and newly found, we have now identified biopsy-
proven DN as an independent risk factor for mortality. Our
results regarding the increase in mortality in DN patients may
be ascribed to two possible causes: (i) the known increased risk
of mortality in diabetic kidney disease patients and (ii) NDRD
can benefit from specific treatments that may be able to modify
renal and patient prognosis.
Our study has several limitations. Overall, 78% of patients
in this cohort are Caucasian; therefore, the renal histology and
renal prognosis may be different from other populations. A high
percentage of kidney biopsies were reported as unclassifiable,
limiting the analyses. Furthermore, the glycated haemoglobin
data, microalbuminuria and urine protein/creatinine ratio were
eliminated from the analysis due to the high percentage of
missed values.
In conclusion, the number of renal biopsies performed in
patients with diabetes has been increasing in recent times. In
our Spanish cohort, 60% of biopsies in patients with diabetes
yielded a NDRD with or without DN. The identification of risk
factors for NDRD of DM patients may help us identify patients
at risk for NDRD and subsequently indicate the specific treat-
ment for improving renal and patient prognosis. To our knowl-
edge, this study is the first to demonstrate that diabetic patients
with biopsy-proven DN have worse renal and survival progno-
ses. Further studies are necessary to determine the importance
of renal biopsy when it comes to treatment and renal prognosis
in daily clinical practice with diabetic patients.
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